p53 and Mdm2: Not all cells are equal

Journal of Pathology

Volumn 213, Issue 4, 2007, Pages 357-359

  Coates, P J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer therapy; Development; Mdm2; p53; Progenitor cells

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL TYPE; CONTROLLED STUDY; EPITHELIUM CELL; GENE DELETION; GENE INACTIVATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SPERMATOGENESIS; STEM CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL DIFFERENTIATION; HEMATOPOIESIS; HUMANS; MALE; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; SPERMATOGENESIS; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36749041487     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2275     Document Type: Review

References (23)

1. Coates PJ, Lorimore SA, Wright EG. Cell and tissue responses to genotoxic stress. J Pathol 2005;205:221-235.
2. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112- 126.
3. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Rev Cancer 2006;6:909-923.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
5. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
6. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A 1993;90:10914-10921.
7. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003;21:277-284.
8. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996;13:2575-2587.
9. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108:1843-1848.
10. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 1997;16:1381-1390.
11. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997;16:1391-1400.
12. Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, et al. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000;19:649-660.
13. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001;20:4601-4612.
14. Coates PJ, Lorimore SA, Lindsay KJ, Wright EG. Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility? J Pathol 2003;201:377-388.
15. Hall PA, Lane DP. Tumor suppressors: a developing role for p53? Curr Biol 1997;7:R144-147.
16. Zambetti GP, Horwitz EM, Schipani E. Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development. J Cell Biol 2006;172:795-797.
17. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, et al. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 2007;213:360-368.
18. Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, et al. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 2007;109:2630-2633.
19. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006;20:125-131.
20. Coates PJ. Regulating p73 isoforms in human tumours. J Pathol 2006;210:385-389.
21. Nylander K, Vbjtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
22. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
23. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-259.